WO2021251734A1 - O-포스포세린 배출 단백질 변이체 및 이를 이용한 o-포스포세린, 시스테인 및 이의 유도체의 생산방법 - Google Patents
O-포스포세린 배출 단백질 변이체 및 이를 이용한 o-포스포세린, 시스테인 및 이의 유도체의 생산방법 Download PDFInfo
- Publication number
- WO2021251734A1 WO2021251734A1 PCT/KR2021/007172 KR2021007172W WO2021251734A1 WO 2021251734 A1 WO2021251734 A1 WO 2021251734A1 KR 2021007172 W KR2021007172 W KR 2021007172W WO 2021251734 A1 WO2021251734 A1 WO 2021251734A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phosphoserine
- polypeptide
- activity
- amino acid
- seq
- Prior art date
Links
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 title claims abstract description 193
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 title claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 30
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 235000018417 cysteine Nutrition 0.000 title claims abstract description 29
- 108090000623 proteins and genes Proteins 0.000 title abstract description 140
- 102000004169 proteins and genes Human genes 0.000 title abstract description 93
- 235000018102 proteins Nutrition 0.000 title abstract description 91
- 230000000694 effects Effects 0.000 claims description 143
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 141
- 229920001184 polypeptide Polymers 0.000 claims description 138
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 138
- 150000001413 amino acids Chemical group 0.000 claims description 129
- 108091033319 polynucleotide Proteins 0.000 claims description 96
- 102000040430 polynucleotide Human genes 0.000 claims description 96
- 239000002157 polynucleotide Substances 0.000 claims description 96
- 244000005700 microbiome Species 0.000 claims description 72
- 230000029142 excretion Effects 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 55
- 230000001747 exhibiting effect Effects 0.000 claims description 49
- 239000013598 vector Substances 0.000 claims description 45
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 33
- 239000004474 valine Substances 0.000 claims description 33
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 29
- 229960000310 isoleucine Drugs 0.000 claims description 29
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 29
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 claims description 23
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 21
- 241000588724 Escherichia coli Species 0.000 claims description 18
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 16
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 16
- 239000004473 Threonine Substances 0.000 claims description 16
- 235000003704 aspartic acid Nutrition 0.000 claims description 16
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 16
- 238000012258 culturing Methods 0.000 claims description 12
- 150000001944 cysteine derivatives Chemical class 0.000 claims description 10
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims description 9
- 102100037579 D-3-phosphoglycerate dehydrogenase Human genes 0.000 claims description 7
- 108010038555 Phosphoglycerate dehydrogenase Proteins 0.000 claims description 7
- 102000030592 phosphoserine aminotransferase Human genes 0.000 claims description 5
- 108010088694 phosphoserine aminotransferase Proteins 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 102100021762 Phosphoserine phosphatase Human genes 0.000 claims description 4
- 108010076573 phosphoserine phosphatase Proteins 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 claims 1
- 150000001945 cysteines Chemical class 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 48
- 229940024606 amino acid Drugs 0.000 description 44
- 239000002773 nucleotide Substances 0.000 description 33
- 125000003729 nucleotide group Chemical group 0.000 description 33
- 239000002609 medium Substances 0.000 description 30
- 210000000349 chromosome Anatomy 0.000 description 26
- 230000014509 gene expression Effects 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 24
- 238000006467 substitution reaction Methods 0.000 description 23
- 101150103854 yhhS gene Proteins 0.000 description 22
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 21
- 229960001153 serine Drugs 0.000 description 19
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 17
- 235000004400 serine Nutrition 0.000 description 17
- 102000015841 Major facilitator superfamily Human genes 0.000 description 16
- 108050004064 Major facilitator superfamily Proteins 0.000 description 16
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 15
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 15
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 14
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 14
- 239000004472 Lysine Substances 0.000 description 14
- 238000004925 denaturation Methods 0.000 description 14
- 230000036425 denaturation Effects 0.000 description 14
- 238000006116 polymerization reaction Methods 0.000 description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 13
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 235000008521 threonine Nutrition 0.000 description 13
- 108020004705 Codon Proteins 0.000 description 12
- 108030001910 O-phosphoserine sulfhydrylases Proteins 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 238000012986 modification Methods 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 230000035772 mutation Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 101150003830 serC gene Proteins 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 8
- 230000004952 protein activity Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 238000000137 annealing Methods 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 6
- -1 aromatic amino acids Chemical class 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 4
- 108010021466 Mutant Proteins Proteins 0.000 description 4
- 102000008300 Mutant Proteins Human genes 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 229960004308 acetylcysteine Drugs 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000588722 Escherichia Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004201 L-cysteine Substances 0.000 description 3
- 235000013878 L-cysteine Nutrition 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 101150033014 rhtB gene Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 150000003680 valines Chemical class 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000186146 Brevibacterium Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 208000034693 Laceration Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 102000054767 gene variant Human genes 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 108091005573 modified proteins Proteins 0.000 description 2
- 102000035118 modified proteins Human genes 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- NLQIBSKINOPHNA-FQEVSTJZSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]sulfanylpropanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CSCC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 NLQIBSKINOPHNA-FQEVSTJZSA-N 0.000 description 1
- WFDQTEFRLDDJAM-LURJTMIESA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-methylsulfanylpropanoic acid Chemical compound CSC[C@@H](C(O)=O)NC(=O)OC(C)(C)C WFDQTEFRLDDJAM-LURJTMIESA-N 0.000 description 1
- ULBLKXPBISVARU-BYPYZUCNSA-N (2r)-2-amino-3-(1,3-thiazol-2-ylsulfanyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CSC1=NC=CS1 ULBLKXPBISVARU-BYPYZUCNSA-N 0.000 description 1
- CHRJYKJYNAKSHG-VIFPVBQESA-N (2r)-2-amino-3-(4-methylphenyl)sulfanylpropanoic acid Chemical compound CC1=CC=C(SC[C@H](N)C(O)=O)C=C1 CHRJYKJYNAKSHG-VIFPVBQESA-N 0.000 description 1
- JULROCUWKLNBSN-IMJSIDKUSA-N (2r)-2-amino-3-[[(2r)-2-amino-2-carboxyethyl]diselanyl]propanoic acid Chemical compound OC(=O)[C@@H](N)C[Se][Se]C[C@H](N)C(O)=O JULROCUWKLNBSN-IMJSIDKUSA-N 0.000 description 1
- XRPOWEFAFQZLRI-YFKPBYRVSA-N (2r)-2-amino-3-thiophen-2-ylsulfanylpropanoic acid Chemical compound OC(=O)[C@@H](N)CSC1=CC=CS1 XRPOWEFAFQZLRI-YFKPBYRVSA-N 0.000 description 1
- YOJXPNNNKZABFE-BXRBKJIMSA-N (2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.OC[C@H](N)C(O)=O YOJXPNNNKZABFE-BXRBKJIMSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- VHPXSBIFWDAFMB-UHFFFAOYSA-N 2-amino-Delta(2)-thiazoline-4-carboxylic acid Chemical compound NC1=[NH+]C(C([O-])=O)CS1 VHPXSBIFWDAFMB-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- ADVPTQAUNPRNPO-REOHCLBHSA-M 3-sulfino-L-alanine(1-) Chemical compound [O-]C(=O)[C@@H]([NH3+])CS([O-])=O ADVPTQAUNPRNPO-REOHCLBHSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101710151325 B2 protein Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- GGLZPLKKBSSKCX-RXMQYKEDSA-N D-ethionine Chemical compound CCSCC[C@@H](N)C(O)=O GGLZPLKKBSSKCX-RXMQYKEDSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 1
- XVOYSCVBGLVSOL-REOHCLBHSA-N L-cysteic acid Chemical compound OC(=O)[C@@H](N)CS(O)(=O)=O XVOYSCVBGLVSOL-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010036940 Levansucrase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 101710161951 O-phosphoserine sulfhydrylase Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 101710190786 PI protein Proteins 0.000 description 1
- 101150038013 PIR gene Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000588768 Providencia Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001522 polyglycol ester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1096—Transferases (2.) transferring nitrogenous groups (2.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/12—Methionine; Cysteine; Cystine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01095—Phosphoglycerate dehydrogenase (1.1.1.95)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01065—O-Phosphoserine sulfhydrylase (2.5.1.65)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y206/00—Transferases transferring nitrogenous groups (2.6)
- C12Y206/01—Transaminases (2.6.1)
- C12Y206/01052—Phosphoserine transaminase (2.6.1.52)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03003—Phosphoserine phosphatase (3.1.3.3)
Definitions
- the present application relates to an O-phosphoserine (OPS) excreting protein variant and a method for producing O-phosphoserine, cysteine and derivatives of cysteine using the same.
- OPS O-phosphoserine
- L-cysteine is an important amino acid for sulfur metabolism in all living things. It is used not only for the synthesis of in vivo proteins such as hair keratin, glutathione, biotin, methionine and other sulfur-containing metabolites, but also as a precursor for coenzyme A biosynthesis. do.
- O-phosphoserine O- A method of fermenting and producing phosphoserine (hereinafter “OPS”) and then reacting it with a sulfide under the catalysis of O-phosphoserine sulfhydrylase (hereinafter “OPSS”) to convert it to L-cysteine (USA) US 8557549 B2) is known.
- OPS O-phosphoserine
- the present inventors completed the present application by identifying a variant with increased activity in the release factor capable of smoothly draining the OPS produced in the OPS-producing strain out of the cell, and confirming that OPS release is improved due to the variant. .
- One object of the present application is to provide a polypeptide exhibiting O-phosphoserine (OPS) excretion activity.
- OPS O-phosphoserine
- Another object of the present application is to provide a polynucleotide encoding the polypeptide of the present application.
- Another object of the present application is to provide a vector comprising the polynucleotide of the present application.
- Another object of the present application is to provide an O-phosphoserine-producing microorganism comprising any one or more of the polypeptide of the present application, the polynucleotide of the present application, and the vector of the present application.
- Another object of the present application is to provide a method for producing O-phosphoserine, comprising the step of culturing the O-phosphoserine-producing microorganism of the present application in a medium.
- Another object of the present application is a) O-phosphoserine-producing microorganisms comprising any one or more of a) a polypeptide of the present application, a polynucleotide encoding the polypeptide of the present application, and a vector comprising the polynucleotide of the present application culturing in a medium to produce O-phosphoserine or a medium containing the same; And b) in the presence of O-phosphoserine sulfliydrylase (O-phosphoserine sulfliydrylase, OPSS) or a microorganism expressing the same, reacting the O-phosphoserine produced in step a) or a medium containing the same with sulfide
- O-phosphoserine sulfliydrylase O-phosphoserine sulfliydrylase
- isoleucine (I) at position 241 is threonine (T)
- position corresponding to position 246 of aspartic acid (D) is valine (V)
- valine (V) at position 330 is replaced with isoleucine (I)
- the amino acid at position 88 is phenylalanine
- It provides a polypeptide exhibiting O-phosphoserine (OPS) excretion activity, having a sequence in which the amino acid at the position corresponding to position 207 is lysine (K).
- OPS O-phosphoserine
- OPS OPS sulfhydrylase
- polypeptide exhibiting OPS excretion activity refers to a membrane protein having an activity capable of excreting OPS out of a cell.
- the membrane protein may be derived from E. coli.
- the polypeptide exhibiting the O-phosphoserine excretion activity of the present application may be a YhhS major facilitator superfamily (MFS) transporter or a variant thereof.
- MFS major facilitator superfamily
- the polypeptide of the present application exhibits enhanced OPS excretion activity than the wild-type YhhS MFS (major facilitator superfamily) transporter, which has been identified as a protein exhibiting OPS excretion activity from E. coli whose growth inhibition is released under conditions in which an excess of OPS is present. It may be a variant of the YhhS MFS transporter shown.
- variant means that one or more amino acids differ from the recited sequence in conservative substitution and/or modification, but the function of the protein ( Functions) or properties (properties) are maintained.
- a variant differs from the identified sequence by several amino acid substitutions, deletions or additions.
- Such variants can generally be identified by modifying one or more amino acids in the amino acid sequence of the protein and evaluating the properties of the modified protein. That is, the ability of the variant may be increased, unchanged, or decreased compared to the native protein.
- some variants may include variants in which one or more portions, such as an N-terminal leader sequence or a transmembrane domain, have been removed.
- variants may include variants in which a portion is removed from the N- and/or C-terminus of the mature protein.
- variant may include terms such as mutant, modified, mutated protein, mutant polypeptide, and mutant (in English, modified, modified protein, modified polypeptide, mutant, mutein, divergent, variant, etc.) may be used, If it is a term used in a mutated meaning, it is not limited thereto.
- the mutant may have increased activity of the mutated protein compared to the natural wild-type or unmodified protein, but is not limited thereto.
- conservative substitution refers to substituting one amino acid with another amino acid having similar structural and/or chemical properties. Such variants may have, for example, one or more conservative substitutions while still retaining one or more biological activities. Such amino acid substitutions may generally occur based on similarity in the polarity, charge, solubility, hydrophobicity, hydrophilicity and/or amphipathic nature of the residues. For example, among amino acids with electrically charged amino acids, positively charged (basic) amino acids are arginine, lysine, and histidine, and negatively charged (acidic) amino acids are glutamic acid and arpartate.
- nonpolar amino acids include glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan and proline
- polar or hydrophilic ( hydrophilic) amino acids include serine, threonine, cysteine, tyrosine, asparagine and glutamine
- aromatic amino acids among the amino acids include phenylalanine, tryptophan and tyrosine.
- variants may contain deletions or additions of amino acids that have minimal effect on the properties and secondary structure of the polypeptide.
- the polypeptide may be conjugated with a signal (or leader) sequence at the N-terminus of the protein involved in the transfer of the protein either co-translationally or post-translationally.
- the polypeptide may also be conjugated with other sequences or linkers to enable identification, purification, or synthesis of the polypeptide.
- polypeptide exhibiting OPS excretion activity of the present application a) of the amino acid sequence of SEQ ID NO: 11, isoleucine (I) at position 241 is threonine (T), and aspartic acid at position 246 (D) comprises a substitution of valine (V), the valine (V) at the position corresponding to position 330 with isoleucine (I), b) the amino acid at the position 88 is phenylalanine, c) 207 A polypeptide exhibiting OPS excretion activity comprising a sequence in which the amino acid at the position corresponding to the position is lysine (K) or a) of the amino acid sequence of SEQ ID NO: 11 isoleucine (I) at the position 241 corresponding to threonine (T) wherein aspartic acid (D) at position 246 is replaced with valine (V) and valine (V) at position 330 is replaced with isoleucine (I), b) corresponding to position
- the valine (V) at the position corresponding to position 330 comprises a substitution with isoleucine (I), b) the amino acid at the position corresponding to position 88 is phenylalanine, c) corresponding to position 207
- a polypeptide exhibiting OPS excretion activity comprising a sequence in which the amino acid at the position of comprising the substitution of aspartic acid (D) in the position corresponding to the position to valine (V) and the valine (V) in the position corresponding to position 330 to isoleucine (I), b) the position corresponding to position 88;
- the amino acid may be phenylalanine
- c) may be a polypeptide exhibiting OPS excretion activity consisting
- polypeptide having an amino acid sequence substantially exhibiting OPS excretion ability as a sequence having such identity, the amino acid position other than the 88th, 207th, 241th, 246th, and 330th amino acid positions of the amino acid sequence of SEQ ID NO: 11 It is apparent that polypeptide variants in which some sequences of are deleted, modified, substituted or added are also included within the scope of the present application.
- polypeptide exhibiting OPS excretion activity may be a polypeptide having the amino acid sequence of SEQ ID NO: 1.
- the polypeptide exhibiting O-phosphoserine excretion activity having the amino acid sequence of SEQ ID NO: 1 is a polypeptide exhibiting O-phosphoserine excretion activity comprising the amino acid sequence of SEQ ID NO: 1, described as the amino acid sequence of SEQ ID NO: 1
- a polypeptide exhibiting O-phosphoserine excretion activity a polypeptide exhibiting O-phosphoserine excretion activity consisting essentially of the amino acid sequence of SEQ ID NO: 1, or O-phosphoserine consisting of the amino acid sequence of SEQ ID NO: 1 It may be a polypeptide that exhibits excretion activity.
- the polypeptide exhibiting O-phosphoserine excretion activity of the present application does not exclude the addition of meaningless sequences before and after the amino acid sequence of SEQ ID NO: 1.
- SEQ ID NO: 1 may refer to an amino acid sequence exhibiting OPS excretion activity.
- SEQ ID NO: 1 may be an amino acid sequence constituting a variant of the YhhS MFS transporter, which is a protein exhibiting OPS excretion activity encoded by the yhhS gene.
- the amino acid sequence of the YhhS MFS transporter which is a protein exhibiting OPS excretion activity encoded by the yhhS gene, can be obtained from a known database, GenBank of NCBI.
- the amino acid sequence of the YhhS MFS transporter may be, for example, SEQ ID NO: 11.
- the amino acid sequence of MFS transporters YhhS E. coli (Escherichia coli, E. coli) may be an amino acid sequence derived from, but not limited thereto.
- a) isoleucine (I) at position 241 is threonine (T), and aspartic acid (D) at position 246 ) is valine (V), valine (V) at position 330 contains a substitution with isoleucine (I), b) the amino acid at position 88 is phenylalanine, c) at position 207 Having a sequence in which the amino acid at the corresponding position is lysine (K), a polypeptide exhibiting O-phosphoserine (OPS) excretion activity or a poly having O-phosphoserine excretion activity having the amino acid sequence of SEQ ID NO: 1
- a polynucleotide encoding a peptide is provided.
- polypeptides exhibiting SEQ ID NO: 11, SEQ ID NO: 1, O-phosphoserine and O-phosphoserine excretion activity are the same as described above.
- polynucleotide refers to a DNA or RNA strand of a certain length or more as a polymer of nucleotides in which nucleotide monomers are connected in a long chain form by covalent bonds.
- the polynucleotide may be included without limitation as long as it is a polynucleotide encoding a polypeptide exhibiting OPS excretion activity of the present application.
- the gene encoding the amino acid sequence of the OPS excretion protein may be a yhhS gene.
- the gene may be derived from E. coli ( Escherichia coli , E. coli ), but is not limited thereto.
- the polynucleotide encoding the polypeptide exhibiting the OPS excretion activity of the present application may have or include a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO: 1.
- the polynucleotide encoding the polypeptide exhibiting the OPS excretion activity of the present application may consist of or consist essentially of a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO: 1.
- various modifications may be made to the coding region within a range that does not change the amino acid sequence of the polypeptide due to codon degeneracy or in consideration of codons preferred in the organism in which the polypeptide is to be expressed.
- the polynucleotide of the present application may include or have, for example, a nucleotide sequence having at least 80%, 90%, 95% or 99% or more homology or identity with the nucleotide sequence of SEQ ID NO: 2, but is not limited thereto.
- the polynucleotide of the present application may consist of or consist essentially of a nucleotide sequence having at least 80%, 90%, 95% or 99% homology or identity with the nucleotide sequence of SEQ ID NO: 2, but is limited thereto doesn't happen
- the polynucleotide of the present application is hybridized with a probe that can be prepared from a known gene sequence, for example, a complementary sequence to all or part of the base sequence under stringent conditions, thereby obtaining the amino acid sequence of SEQ ID NO: 1 Any coding sequence may be included without limitation.
- the "stringent condition” means a condition that enables specific hybridization between polynucleotides. Such conditions are described in, for example, J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press, Cold Spring Harbor, New York, 1989; FM Ausubel et al., Current Protocols in Molecular Biology. , John Wiley & Sons, Inc., New York).
- polynucleotides having high homology or identity with each other 40% or more, specifically 90% or more, more specifically 95% or more, more specifically 97% or more, especially 99% or more homology or identity with each other
- Conditions under which polynucleotides hybridize with each other and polynucleotides with lower homology or identity do not hybridize, or wash conditions of conventional southern hybridization at 60° C., 1 ⁇ SSC, 0.1% SDS, specifically 60° C. , 0.1 ⁇ SSC, 0.1% SDS, more specifically at a salt concentration and temperature equivalent to 68° C., 0.1 ⁇ SSC, 0.1% SDS, washing conditions once, specifically two to three times.
- Hybridization requires that two nucleic acids have complementary sequences, although mismatch between bases is possible depending on the stringency of hybridization.
- the term "complementary" is used to describe the relationship between nucleotide bases capable of hybridizing to each other.
- adenosine is complementary to thymine
- cytosine is complementary to guanine.
- the polynucleotides of the present application may also include substantially similar nucleic acid sequences as well as isolated nucleic acid fragments complementary to the overall sequence.
- the term 'homology' or 'identity' refers to a degree related to two given amino acid sequences or base sequences, and may be expressed as a percentage.
- the terms homology and identity can often be used interchangeably.
- Sequence homology or identity of a conserved polypeptide or polynucleotide is determined by standard alignment algorithms, with default gap penalties established by the program used may be used.
- Substantially, homologous or identical sequences generally have moderate or high stringency conditions along at least about 50%, 60%, 70%, 80% or 90% of the entire or full-length sequence. It can hybridize under stringent conditions. Hybridization is also contemplated for polynucleotides containing degenerate codons instead of codons in the polynucleotides.
- a GAP program can be defined as the total number of symbols in the shorter of two sequences divided by the number of similarly aligned symbols (ie, nucleotides or amino acids).
- Default parameters for the GAP program are: (1) a binary comparison matrix (containing values of 1 for identity and 0 for non-identity) and Schwartz and Dayhoff, eds., Atlas Of Protein Sequence And Structure, National Biomedical Research Foundation , pp. 353-358 (1979), Gribskov et al (1986) Nucl. Acids Res. 14: weighted comparison matrix of 6745 (or EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap (or a gap opening penalty of 10, a gap extension penalty of 0.5); and (3) no penalty for end gaps.
- polypeptide or polynucleotide sequences have homology, similarity or identity can be confirmed by comparing the sequences by Southern hybridization experiments under defined stringent conditions, and the defined appropriate hybridization conditions are within the scope of the art. , and can be determined by a method well known to those skilled in the art (eg, J. Sambrook et al., supra).
- polynucleotides having homology or identity can be detected using hybridization conditions including a hybridization step at a Tm value of 55° C. and using the above-described conditions.
- the Tm value may be 60°C, 63°C, or 65°C, but is not limited thereto and may be appropriately adjusted by those skilled in the art depending on the purpose.
- a) isoleucine (I) at position 241 is threonine (T), and aspartic acid (D) at position 246 ) is valine (V), valine (V) at position 330 contains a substitution with isoleucine (I), b) the amino acid at position 88 is phenylalanine, c) at position 207
- a vector comprising a polynucleotide encoding a polypeptide exhibiting shedding activity is provided.
- Polypeptides and polynucleotides exhibiting SEQ ID NO: 11, SEQ ID NO: 1, O-phosphoserine, and O-phosphoserine excretion activity are the same as described above.
- the term "vector” refers to a DNA preparation containing the nucleotide sequence of a polynucleotide encoding the target polypeptide or protein operably linked to a suitable regulatory sequence so that the target polypeptide or protein can be expressed in a suitable host.
- suitable regulatory sequences may include a promoter capable of initiating transcription, an optional operator sequence for regulating such transcription, a suitable mRNA ribosome binding site sequence, and sequences regulating the termination of transcription and translation.
- the vector After transformation into an appropriate host cell, the vector can replicate or function independently of the host genome, and can be integrated into the genome itself.
- the vector used in the present application is not particularly limited as long as it is capable of replication in a host cell, and any vector known in the art may be used.
- Examples of commonly used vectors include natural or recombinant plasmids, cosmids, viruses and bacteriophages.
- pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, and Charon21A may be used as a phage vector or a cosmid vector
- pBR-based, pUC-based, pBluescriptII-based plasmid vectors may be used.
- pGEM-based, pTZ-based, pCL-based, pSK-based, pSKH-based and pET-based and the like can be used.
- pCL, pSK, pSKH130, pDZ, pACYC177, pACYC184, pECCG117, pUC19, pBR322, pMW118, pCC1BAC vectors and the like may be used.
- Insertion of the polynucleotide into the chromosome may be achieved by any method known in the art, for example, homologous recombination, but is not limited thereto.
- the vector may further include a selection marker for confirming whether or not the chromosome is inserted.
- the selection marker is used to select cells transformed with the vector, that is, to determine whether a target nucleic acid molecule is inserted, and selectable such as drug resistance, auxotrophic resistance, resistance to cytotoxic agents, or expression of a surface variant protein. Markers that confer a phenotype can be used. In an environment treated with a selective agent, only the cells expressing the selectable marker survive or exhibit other expression traits, so that the transformed cells can be selected.
- the term "transformation” refers to introducing a vector including a polynucleotide encoding a target polypeptide or protein into a host cell so that the polypeptide or protein encoded by the polynucleotide can be expressed in the host cell. it means. As long as the transformed polynucleotide can be expressed in the host cell, it may include all of them regardless of whether they are inserted into the chromosome of the host cell or located outside the chromosome. In addition, the polynucleotide may include DNA and RNA encoding a target polypeptide or protein.
- the polynucleotide may be introduced into a host cell and expressed in any form, as long as it can be expressed.
- the polynucleotide may be introduced into a host cell in the form of an expression cassette, which is a gene construct including all elements necessary for self-expression.
- the expression cassette may include a promoter operably linked to the polynucleotide, a transcription termination signal, a ribosome binding site, and a translation termination signal.
- the expression cassette may be in the form of an expression vector capable of self-replication.
- the polynucleotide may be introduced into a host cell in its own form and operably linked to a sequence required for expression in the host cell, but is not limited thereto.
- operably linked means that a promoter sequence that initiates and mediates transcription of a polynucleotide encoding a target polypeptide or protein of the present application and the gene sequence are functionally linked.
- a) isoleucine (I) at position 241 is threonine (T), and aspartic acid (D) at position 246 ) is valine (V), valine (V) at position 330 contains a substitution with isoleucine (I), b) the amino acid at position 88 is phenylalanine, c) at position 207 Having a sequence in which the amino acid at the corresponding position is lysine (K), a polypeptide exhibiting O-phosphoserine (OPS) excretion activity or a poly having O-phosphoserine excretion activity having the amino acid sequence of SEQ ID NO: 1 It provides an O-phosphoserine-producing microorganism comprising any one or more of a vector comprising a peptide, a polynucleotide encoding the polypeptide of the present application, and a polynucleotide encoding the
- Polypeptides, polynucleotides and vectors exhibiting SEQ ID NO: 11, SEQ ID NO: 1, O-phosphoserine, and O-phosphoserine excretion activity are the same as described above.
- O-phosphoserine (OPS) producing microorganism refers to a microorganism having a naturally weak OPS-producing ability or a microorganism to which OPS-producing ability is endowed by natural or artificial genetic modification in a parent strain without OPS-producing ability means Specifically, the microorganism may be a microorganism expressing a polypeptide having the amino acid sequence of SEQ ID NO: 1, but is not limited thereto.
- the "OPS-producing microorganism” may be used interchangeably with "a microorganism having an OPS-producing ability", "OPS-producing strain", and "OPS-producing strain”.
- the microorganism is a vector comprising a polypeptide exhibiting O-phosphoserine excretion activity of the present application, a polynucleotide encoding the polypeptide of the present application, and a polynucleotide of the present application
- a polypeptide exhibiting O-phosphoserine excretion activity of the present application a polypeptide exhibiting O-phosphoserine excretion activity of the present application
- a polynucleotide encoding the polypeptide of the present application and a polynucleotide of the present application
- the production of OPS may be increased compared to the wild-type or pre-modified microorganism.
- the term "enhanced compared to intrinsic activity” means that the activity of the original microorganism is increased when compared with the activity of the protein in its natural state.
- the term “to be expressed” refers to a state in which a target polypeptide or protein is introduced into a microorganism or modified to be expressed in the microorganism.
- the target polypeptide or protein is a polypeptide or protein existing in a microorganism, it may mean a state in which its activity is enhanced compared to before endogenous or modified.
- the term “enhancement” of polypeptide or protein activity means that the activity of the polypeptide or protein is increased compared to the intrinsic activity.
- the "intrinsic activity” refers to the activity of a specific polypeptide or protein originally possessed by the parent strain or unmodified microorganism before the transformation when the trait is changed due to genetic mutation caused by natural or artificial factors. This may be used interchangeably with “activity before modification”.
- “Enhancement” or “increase” in the activity of a polypeptide or protein compared to the intrinsic activity means that it is improved compared to the activity of a specific polypeptide or protein originally possessed by the parent strain or unmodified microorganism before transformation.
- the "increase in activity” may be achieved by introducing an exogenous polypeptide or protein or enhancing the activity of the endogenous polypeptide or protein, but specifically, it may be achieved through enhancing the activity of the endogenous polypeptide or protein. have. Whether the activity of the polypeptide or protein is enhanced can be confirmed from an increase in the activity level, expression level, or amount of a product discharged from the corresponding polypeptide or protein.
- the polypeptide or protein that is, the target polypeptide or protein to be strengthened in the activity, may be a mutant of the YhhS MFS transporter, specifically, it exhibits enhanced OPS excretion activity than the wild-type YhhS MFS transporter. It may be a variant of the YhhS MFS transporter shown, but is not limited thereto.
- the product excreted from the corresponding polypeptide or protein may be O-phosphoserine, but is not limited thereto.
- the enhancement of the activity of the polypeptide or protein can be applied by various methods well known in the art, and may not be limited as long as the activity of the target polypeptide or protein can be enhanced compared to the microorganism before modification.
- the method is not limited thereto, but may be one using genetic engineering or protein engineering.
- the method for enhancing polypeptide or protein activity using the genetic engineering is, for example,
- the method for enhancing polypeptide or protein activity using the protein engineering may be performed by, for example, a method of selecting an exposed site by analyzing the tertiary structure of the polypeptide or protein and modifying or chemically modifying it, etc. It is not limited thereto.
- the increase in the intracellular copy number of the gene or polynucleotide encoding the polypeptide or protein can be performed by any method known in the art, for example, the gene or polynucleotide encoding the polypeptide or protein is operable. This can be accomplished by introducing a linked, host-independently replicated and functional vector into a host cell. Alternatively, a vector capable of inserting the gene or polynucleotide into a chromosome in the host cell, to which the gene is operably linked, may be introduced into the host cell, but is not limited thereto. The vector is the same as described above.
- the method of replacing a gene expression control sequence on a chromosome encoding a polypeptide or protein with a sequence with strong activity is any method known in the art, for example, a nucleic acid to further enhance the activity of the expression control sequence Deletion, insertion, non-conservative or conservative substitution of the sequence, or by inducing a mutation in the sequence through a combination thereof, or by replacing the sequence with a nucleic acid sequence having a stronger activity.
- the expression control sequence is not particularly limited thereto, but may include a promoter, an operator sequence, a sequence encoding a ribosome binding site, a sequence for controlling termination of transcription and translation, and the like.
- the method may specifically be to link a strong heterologous promoter instead of the original promoter, but is not limited thereto.
- CJ7 promoter (US 7662943 B2)
- CJ1 promoter (US 7662943 B2)
- lac promoter Trp promoter
- trc promoter tac promoter
- lambda phage PR promoter PL promoter
- tet Promoters may be included, but are not limited thereto.
- the method of modifying the nucleotide sequence of the initiation codon or 5'-UTR region of the polypeptide or protein is any method known in the art, for example, the intrinsic initiation of the intrinsic initiation codon of the polypeptide or protein. It may be substituted with another initiation codon having a higher polypeptide or protein expression rate than the codon, but is not limited thereto.
- the method for modifying a polynucleotide sequence on a chromosome to increase the polypeptide or protein activity is any method known in the art, for example, a nucleic acid sequence to further enhance the activity of the polynucleotide sequence. Deletion, insertion, non-conservative or conservative substitution or a combination thereof may be performed by inducing a mutation in the expression control sequence, or replacing it with an improved polynucleotide sequence to have stronger activity. The replacement may specifically be to insert the gene into the chromosome by homologous recombination, but is not limited thereto.
- the vector used may further include a selection marker for confirming whether or not the chromosome is inserted.
- the selection marker is the same as described above.
- the introduction of a foreign polynucleotide exhibiting the activity of the polypeptide or protein can be performed by any method known in the art, for example, encoding a polypeptide or protein exhibiting the same/similar activity as the polypeptide or protein. It can be carried out by introducing a foreign polynucleotide, or a polynucleotide having a codon-optimized variant thereof into a host cell.
- the foreign polynucleotide may be used without limitation in its origin or sequence as long as it exhibits the same/similar activity as the polypeptide or protein.
- the introduced foreign polynucleotide can be introduced into the host cell by optimizing its codon so that the optimized transcription and translation are performed in the host cell.
- the introduction can be carried out by appropriately selecting a known transformation method by those skilled in the art, and by expressing the introduced polynucleotide in a host cell, a polypeptide or protein is produced and its activity can be increased.
- the combination of the methods may be performed by applying any one or more methods of 1) to 5) together.
- Such enhancement of the polypeptide or protein activity is, the activity or concentration of the corresponding polypeptide or protein is increased relative to the activity or concentration of the polypeptide or protein expressed in the wild-type or pre-modified microbial strain, or the polypeptide or protein
- the amount of the product produced from the protein may be increased, but is not limited thereto.
- strain before modification or "microbe before modification” does not exclude strains containing mutations that may occur naturally in microorganisms, and is either a natural strain itself, or genetic variation caused by natural or artificial factors may mean the strain before the trait is changed.
- pre-modified strain or "pre-modified microorganism” may be used interchangeably with “unmodified strain”, “unmodified strain”, “unmodified microorganism”, “unmodified microorganism” or “reference microorganism”.
- the reference microorganism is a known microorganism that produces OPS, CA07-0012, endogenous SerA (D-3-phosphoglycerate dehydrogenase, D-3-phosphoglycerate dehydrogenase) and SerC (3-phosphoserine).
- Strain CA07-0022/pCL_Prmf-serA*(G336V)-serC (KCCM11103P, US Patent Publication No.
- US 8557549 B2) with enhanced activity of aminotransferase, 3-phosphoserine aminotransferase and endogenous phosphoserine phosphatase (SerB) ) may be strain CA07-0012 (KCCM 11121P, US 8557549 B2) with weakened activity, but is not limited thereto.
- the microorganism of the present application may be a recombinant microorganism produced by transformation with a vector containing a polynucleotide encoding the polypeptide, but is not limited thereto.
- the type of the microorganism of the present application is not particularly limited as long as it can produce OPS, and both prokaryotic and eukaryotic cells are possible, but specifically prokaryotic cells.
- the prokaryotic cells are, for example, Escherichia genus, Erwinia genus, Serratia genus, Providencia genus, Corynebacterium genus and Brevibacterium. ( Brevibacterium ) It may include a microbial strain belonging to the genus, specifically, a microorganism of the genus Escherichia, more specifically Escherichia coli , but may be, but is not limited thereto.
- OPS and L-serine can be produced through SerA, SerC and SerB, which are enzymes in the biosynthetic pathway of L-serine (Ahmed Zahoor, Computational and structural biotechnology journal, vol. 3, 2012 October; Wendisch VF et al., Curr Opin Microbiol. 2006 Jun;9(3):268-74;Peters-Wendisch P et al., Appl Environ Microbiol. 2005 Nov;7 1(ll):7 139 -44.).
- the OPS-producing microorganism of the present application may additionally have a weakened activity of phosphoserine phosphatase (SerB) compared to its intrinsic activity.
- SerB phosphoserine phosphatase
- SerB of the present application has an activity of converting OPS into L-serine (L-serine), the microorganism mutated so that the SerB activity is weakened has a characteristic of accumulating OPS and can be usefully used in the production of OPS.
- SerB of the present application may be a protein having or comprising the amino acid sequence shown in SEQ ID NO: 3, or a protein consisting of or essentially consisting of the amino acid sequence shown in SEQ ID NO: 3, but is not limited thereto.
- the SerB of the present application may have or include an amino acid sequence having at least 80%, 90%, 95% or 99% or more homology or identity to the amino acid sequence set forth in SEQ ID NO: 3 as long as it exhibits SerB activity. .
- the SerB of the present application may consist of or consist essentially of an amino acid sequence having at least 80%, 90%, 95% or 99% or more homology or identity with the amino acid sequence set forth in SEQ ID NO: 3, but is not limited thereto.
- the polynucleotide encoding the SerB may have or include a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO: 3.
- the polynucleotide encoding the SerB may consist of or consist essentially of a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO: 3.
- the polynucleotide encoding SerB of the present application may contain a variety of coding regions within a range that does not change the amino acid sequence of the SerB protein due to codon degeneracy or in consideration of codons preferred in an organism to express the SerB protein. Variations can be made.
- the polynucleotide encoding the SerB of the present application may have or include a nucleotide sequence having at least 80%, 90%, 95% or 99% homology or identity with the nucleotide sequence of SEQ ID NO: 4, and less than 100%.
- polynucleotide encoding the SerB of the present application consists of or consists essentially of a nucleotide sequence having at least 80%, 90%, 95% or 99% or more, and less than 100% homology or identity to the nucleotide sequence of SEQ ID NO: 4 may be, but is not limited thereto.
- the term "weakened compared to intrinsic activity” means that the expression of the enzyme or protein is not expressed at all compared to the natural wild-type strain, the parent strain, or the unmodified strain of the protein, or even if it is expressed, the activity is absent or reduced. means it has been In this case, the decrease is when the activity of the protein is decreased compared to the activity of the protein of the original microorganism due to mutation of the gene encoding the protein, modification of the expression control sequence, deletion of part or all of the gene, and the gene encoding it When the overall protein activity level in the cell is lower than that of the native strain or the strain before transformation due to inhibition of expression or translation inhibition, the concept also includes a combination thereof.
- This attenuation of protein activity can be accomplished in a variety of ways well known in the art.
- Examples of the method include modification of a gene sequence encoding the protein on a chromosome so that the activity of the protein is removed or weakened; a method of modifying an expression control sequence to decrease the expression of the gene encoding the protein; a method of deleting all or part of a gene on a chromosome encoding the protein; a method of introducing an antisense oligonucleotide (eg, antisense RNA) that complementarily binds to the transcriptome of a gene on the chromosome and inhibits translation from the mRNA into a protein; A method of making the attachment of a ribosome impossible by artificially adding a sequence complementary to a Shine-Dalgarno sequence to the front end of the Shine-Dalgarno sequence of the gene encoding the protein to form a secondary structure ; and a method of adding a promoter transcribed in the opposite
- the method for modifying the gene sequence on the chromosome is performed by inducing a laceration mutation such as deletion, insertion, non-conservative or conservative substitution of the gene sequence, or a combination thereof to further weaken the activity of the protein, or It can be carried out by replacing a gene sequence modified to have activity or a gene sequence modified to not have activity.
- the method of modifying the expression control sequence is performed by inducing a mutation in the expression control sequence by deletion, insertion, non-conservative or conservative substitution, or a combination thereof, of a nucleic acid sequence to further weaken the activity of the expression control sequence, or a weaker It can be carried out by replacing it with a nucleic acid sequence having activity.
- the expression control sequence may include a promoter, an operator sequence, a sequence encoding a ribosome binding site, and a sequence controlling the termination of transcription and translation.
- the method of deleting part or all of the gene encoding the protein is performed by replacing a polynucleotide encoding an endogenous target protein in a chromosome with a polynucleotide or a marker gene in which some nucleic acid sequences are deleted through a vector for chromosome insertion in bacteria.
- a method of deleting a gene by homologous recombination may be used.
- "some" is different depending on the type of polynucleotide in the above, it may be specifically 1 to 300, preferably 1 to 100, more preferably 1 to 50, but is not particularly limited thereto. .
- the method of modifying the expression control sequence is performed by inducing mutation in the expression control sequence by deletion, insertion, non-conservative or conservative substitution, or a combination thereof, of the nucleic acid sequence to further weaken the activity of the expression control sequence, or by replacing it with a nucleic acid sequence with weak activity.
- the expression control sequence includes a promoter, an operator sequence, a sequence encoding a ribosome binding site, and a sequence regulating the termination of transcription and translation.
- the method of modifying the gene sequence on the chromosome is performed by inducing the mutation of the laceration by deletion, insertion, non-conservative or conservative substitution of the gene sequence, or a combination thereof to further weaken the activity of the protein, or to exhibit weaker activity. It can be carried out by replacing it with a gene sequence improved to have or a gene sequence improved to have no activity.
- the microorganism producing the OPS of the present application may additionally have enhanced activity of phosphoglycerate dehydrogenase (SerA) or phosphoserine aminotransferase (SerC) compared to the intrinsic activity. have.
- SerA phosphoglycerate dehydrogenase
- SerC phosphoserine aminotransferase
- the SerA is a protein having an activity of converting 3-phosphoglycerate to 3-phospho-hydroxypymvate, and the SerC is 3-phosphohydroxypymvate. It is a protein having the activity of converting rubate into OPS. Therefore, the microorganisms with enhanced SerA or/and SerC activity can be usefully used as OPS-producing strains.
- the SerA is not limited thereto, but may be a protein having or comprising the amino acid sequence set forth in SEQ ID NO: 5 or 6, or a protein consisting of or consisting essentially of the amino acid sequence set forth in SEQ ID NO: 5 or 6.
- the amino acid sequence shown in SEQ ID NO: 5 is a sequence of wild-type SerA
- the amino acid sequence shown in SEQ ID NO: 6 is a sequence of a SerA mutant in which feedback to serine is canceled.
- the SerA of the present application has at least 80%, 90%, homology or identity with the amino acid sequence set forth in SEQ ID NO: 5 or 6, as long as the activity of wild-type SerA or the activity of a SerA mutant in which feedback to serine is canceled, It may have or include, but is not limited to, 95% or 99% or more, and less than 100% amino acid sequence.
- the SerA of the present application has at least 80%, 90% homology or identity to the amino acid sequence set forth in SEQ ID NO. It may consist of or consist essentially of at least 95% or 99% and less than 100% of the amino acid sequence.
- the SerA mutant in which the feedback to serine has been canceled introduces a mutation by inserting the nucleotide of the gene encoding SerA or substituting the gene encoding the wild-type SerA, and its activity from feedback inhibition by serine or glycine It refers to the case of maintaining or enhancing the serine, and SerA variants in which the feedback to serine is canceled are already well known (Grant GA et al., J. Biol. Chem., 39: 5357-5361, 1999; Grant GA). et al., Biochem., 39: 7316-7319, 2000; Grant GA et al., J. Biol. Chem., 276:17844-17850, 2001; Peters-Wendisch P et al., Appl. Microbiol. BiotechnoL, 60:37-441, 2002; US Publication No. 6258573 B1).
- polynucleotide encoding the wild-type SerA or the SerA variant in which feedback for serine is canceled may have or include a nucleotide sequence encoding any one of the amino acid sequences set forth in SEQ ID NOs: 5 to 6.
- polynucleotide encoding the wild type of SerA or the SerA variant in which feedback for serine has been canceled may consist of or consist essentially of a nucleotide sequence encoding any one of the amino acid sequences set forth in SEQ ID NOs: 5 to 6, It is not limited thereto.
- the polynucleotide encoding the wild type of SerA or the SerA variant in which feedback for serine is canceled is due to codon degeneracy or considering codons preferred in an organism to express the polypeptide, wild type or serine of the SerA Various modifications may be made to the coding region within a range that does not change the amino acid sequence of the polypeptide encoding the SerA variant for which feedback for the SerA variant has been canceled.
- the nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO: 5 may be a nucleotide sequence having at least 80%, 90%, 95%, or 99% or more homology or identity with the nucleotide sequence of SEQ ID NO: 7, and SEQ ID NO: 6
- the nucleotide sequence encoding the amino acid sequence described in SEQ ID NO: 8 may be a nucleotide sequence having at least 80%, 90%, 95% or 99% or more homology or identity with the nucleotide sequence of SEQ ID NO: 8, but is not limited thereto.
- the SerC may be, for example, a protein having or comprising the amino acid sequence set forth in SEQ ID NO: 9, or a protein consisting of or essentially consisting of the amino acid sequence set forth in SEQ ID NO: 9, but is not limited thereto.
- the SerC has or comprises an amino acid sequence that is at least 80%, 90%, 95% or 99% or more and less than 100% homology or identity to the amino acid sequence set forth in SEQ ID NO: 9. can, but is not limited thereto.
- the SerC consists of an amino acid sequence having at least 80%, 90%, 95% or 99% or more, and less than 100% homology or identity to the amino acid sequence set forth in SEQ ID NO: 9, or may be compulsory.
- polynucleotide encoding the SerC may have a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO: 9.
- various modifications can be made to the coding region within the range that does not change the amino acid sequence of the polypeptide due to codon degeneracy or in consideration of codons preferred by the organism to express the polypeptide.
- the polynucleotide encoding the SerC may have or include, for example, a nucleotide sequence having 80%, 90%, 95% or 99% or more homology or identity with the nucleotide sequence of SEQ ID NO: 10, but is not limited thereto. .
- polynucleotide encoding SerC of the present application may consist of or consist essentially of a nucleotide sequence having 80%, 90%, 95% or 99% or more homology or identity with the nucleotide sequence of SEQ ID NO: 10.
- microorganism may be a microorganism that further reduces the ability of OPS to enter cells or degrade.
- a) isoleucine (I) at position 241 is threonine (T), and aspartic acid (D) at position 246 ) is valine (V), valine (V) at position 330 contains a substitution with isoleucine (I), b) the amino acid at position 88 is phenylalanine, c) at position 207 A polypeptide exhibiting O-phosphoserine excretion activity having a sequence in which the amino acid at the corresponding position is lysine (K) or a polypeptide exhibiting O-phosphoserine excretion activity having the amino acid sequence of SEQ ID NO: 1, the polypeptide of the present application It provides a method for producing O-phosphoserine, comprising the step of culturing an O-phosphoserine-producing microorganism in a medium, comprising any one or more of the encoding polynucleotide and the vector
- Polypeptides, polynucleotides, vectors and microorganisms exhibiting SEQ ID NO: 11, SEQ ID NO: 1, O-phosphoserine, and O-phosphoserine excretion activity are as described above.
- the term "cultivation” means growing the microorganism in an appropriately controlled environmental condition.
- the culture process of the present application may be made according to a suitable medium and culture conditions known in the art. Such a culture process can be easily adjusted and used by those skilled in the art according to the selected strain.
- the culture may be a batch type, a continuous type, and a fed-batch type, but is not limited thereto.
- Glycine may be provided in the form of purified glycine, yeast extract containing glycine, tryptone, and the concentration contained in the culture medium may be usually 0.1 to 10 g/L, specifically 0.5 to 3 g/L.
- serine may be provided in the form of purified serine, yeast extract containing serine, tryptone, etc., and the concentration contained in the culture medium may be usually 0.1 to 5 g/L, specifically 0.1 to 1 g/L.
- Carbon sources included in the medium include glucose, sucrose, lactose, fructose, maltose, starch, sugars and carbohydrates such as cellulose, oils and fats such as soybean oil, sunflower oil, castor oil, coconut oil, palmitic acid, fatty acids such as stearic acid and linoleic acid, alcohols such as glycerol and ethanol, and organic acids such as acetic acid, and these substances may be used individually or as a mixture, but are not limited thereto.
- sugars and carbohydrates such as cellulose, oils and fats such as soybean oil, sunflower oil, castor oil, coconut oil, palmitic acid, fatty acids such as stearic acid and linoleic acid, alcohols such as glycerol and ethanol, and organic acids such as acetic acid, and these substances may be used individually or as a mixture, but are not limited thereto.
- organic nitrogen sources such as peptone, yeast extract, broth, malt extract, corn steep liquor and soybean wheat and inorganic nitrogen sources such as urea, ammonium sulfate, ammonium chloride, ammonium phosphate, anmonium carbonate and ammonium nitrate are included. and these nitrogen sources may be used alone or in combination, but are not limited thereto.
- potassium hydrogen phosphate dipotassium hydrogen phosphate and the corresponding sodium-containing salt may be included, but the present invention is not limited thereto.
- the medium may contain a metal salt such as magnesium sulfate or iron sulfate, and in addition, amino acids, vitamins and appropriate precursors may be included. These media or precursors may be added to the culture in a batch or continuous manner, but is not limited thereto.
- chemicals such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid and sulfuric acid can be added to the culture in an appropriate manner to adjust the pH of the culture.
- an antifoaming agent such as fatty acid polyglycol ester can be used to suppress foaming.
- oxygen or oxygen-containing gas may be injected into the culture, or nitrogen, hydrogen or carbon dioxide gas may be injected with or without gas to maintain anaerobic and microaerobic conditions.
- the temperature of the culture may be usually 25 °C to 40 °C, specifically 30 °C to 35 °C.
- the incubation period of the culture may be continued until the desired production of useful substances is obtained, and specifically may be 10 to 100 hours. However, it is not limited to these examples.
- the present application may additionally include the step of preparing a medium before the culturing step in the method of the present application, but is not limited thereto.
- the present application may further include the step of recovering the OPS produced in the culturing step in the method of the present application after the culturing step, and the method is a culture method, for example, a batch, continuous or fed-batch culture method. Accordingly, the desired OPS may be isolated and purified from the culture medium using a suitable method known in the art and collected, but is not limited thereto.
- the present application relates to a) in the amino acid sequence of SEQ ID NO: 11, a) isoleucine (I) at position 241 is threonine (T), and aspartic acid at position 246 is (D) comprises a substitution of valine (V), the valine (V) at the position corresponding to position 330 with isoleucine (I), b) the amino acid at the position 88 is phenylalanine, c) 207 Polypeptide showing O-phosphoserine excretion activity having a sequence in which the amino acid at the position corresponding to the second is lysine (K) or O-phosphoserine excretion activity having the amino acid sequence of SEQ ID NO: 1, poly of the present application Culturing the O-phosphoserine-producing microorganism comprising any one or more of a vector comprising a polynucleotide encoding a peptide and a polynucleotide of the present application in a medium
- Polypeptides, polynucleotides, vectors and microorganisms exhibiting SEQ ID NO: 11, SEQ ID NO: 1, O-phosphoserine, and O-phosphoserine excretion activity are as described above.
- derivative refers to a similar compound obtained by chemically changing a part of a certain compound, and usually refers to a compound in which a hydrogen atom or a specific atomic group is substituted with another atom or atomic group.
- cyste derivative refers to a compound in which a hydrogen atom or a specific atomic group of cysteine is substituted with another atom or atomic group.
- it may be a form in which another atom or group is attached to a nitrogen atom of an amine group (-NH 2 ) of cysteine or a sulfur atom of a thiol group (-SH), for example, NAC (N-acetylcysteine), SCMC (S -Carboxymetylcysteine), BOC-CYS(ME)-OH,(R)-S-(2-Amino-2-carboxyethyl)-L-homocysteine, (R)-2-Amino-3-sulfopropionic acid, D-2- Amino-4-(ethylthio)butyric acid, 3-sulfino-L-alanine, Fmoc-Cys(Boc-methyl)-OH, Sel
- cysteine As long as cysteine is produced according to the method of the present application, the conversion to a cysteine derivative can be easily converted into various cysteine derivatives by a method well known in the art.
- the method for producing the cysteine derivative may further include the step of converting the cysteine produced in step b) into a cysteine derivative, for example, by reacting cysteine with an acetylation agent to form NAC ( N-acetylcysteine) or by reacting cysteine with haloacetic acid under basic conditions to synthesize S-Carboxymetylcysteine (SCMC), but is not limited thereto.
- NAC N-acetylcysteine
- SCMC S-Carboxymetylcysteine
- the cysteine derivative is mainly used as a pharmaceutical raw material as an antitussive, a cough reliever, bronchitis, bronchial asthma and sore throat, but is not limited thereto.
- OPS O-phosphoserine sulfhydrylase
- the OPSS includes not only the wild-type OPSS protein, but also a mutant protein in which some of the polynucleotide sequences encoding the OPSS are deleted, substituted, or added, and exhibiting an activity equal to or higher than that of the wild-type OPSS protein. and OPSS protein disclosed in US Patent Publication No. US 8557549 B2 and US Registration Publication US 9127324 B2, and mutant proteins thereof may also be included.
- the sulfide is provided in the form of a liquid or gas due to differences in pH, pressure, and solubility, as well as a solid commonly used in the art, so that sulfide (S 2- ), thiosulfate (thiosulfate, S 2 0 3 ) If it is a sulfide that can be converted to a thiol group (SH group) in the form of 2- ), etc., it can be used without limitation. Specifically, Na 2 S, NaSH, H 2 S, (NH 4 ) 2 S, NaSH, and Na 2 S 2 0 3 that provide a thiol group to the OPS may be used, but are not limited thereto.
- the reaction is a reaction for preparing one cysteine or cysteine derivative by providing one thiol group to one OPS reactor, and the amount of sulfide added in the reaction may be 0.1 to 3 times the molar concentration of OPS, specifically, 1 to 2 It may be a ship, but is not limited thereto.
- the present application may further include the step of recovering the cysteine produced through the reaction step.
- the desired cysteine may be isolated and purified from the reaction solution and collected using a suitable reaction known in the art.
- a) isoleucine (I) at position 241 is threonine (T)
- aspartic acid (D) at position 246 ) is valine (V)
- valine (V) at position 330 contains a substitution with isoleucine (I)
- the amino acid at position 88 is phenylalanine
- c) at position 207 It provides a use for producing a derivative of O-phosphoserine, cysteine or cysteine of a polypeptide having an amino acid sequence of SEQ ID NO: 1 or a polypeptide exhibiting O-phosphoserine excretion activity having a sequence in which the amino acid at the corresponding position is lysine (K) do.
- a) isoleucine (I) at position 241 is threonine (T)
- aspartic acid at position 246 ( D) comprises a substitution for valine (V), the valine (V) at position 330 corresponding to isoleucine (I)
- the amino acid at position 88 is phenylalanine
- c) 207 It provides the use of excreting O-phosphoserine of a polypeptide having an amino acid sequence of SEQ ID NO: 1 or a polypeptide exhibiting O-phosphoserine excretion activity having a sequence in which the amino acid at a position corresponding to lysine (K) is lysine (K) from a microorganism. .
- SEQ ID NO: 11 SEQ ID NO: 1, O-phosphoserine, cysteine, and cysteine are as described above.
- Example 1 Preparation of yhhS major facilitator superfamily (MFS) transporter variants
- OPS O-phosphoserine
- the pCL_PrhtB vector was prepared. PCR was performed with specific primer pairs (SEQ ID NOs: 16 and 17) to secure the rhtB promoter (SEQ ID NO: 15) fragment. For PCR, denaturation at 94°C for 5 minutes, denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and polymerization at 72°C for 1 minute were repeated 30 times, followed by polymerization at 72°C for 5 minutes.
- pCL_PrhtB was obtained by inserting the rhtB promoter fragment into the pCL1920 vector (GeneBank No AB236930) cut with SacI and SmaI. After the pCL_PrhtB vector was cut with SmaI and PstI, the mutant gene fragments obtained through the PCR were cloned using an in-fusion cloning kit (Clontech Laboratories, Inc.). Cloning was performed by reacting at 50° C. for 60 minutes, thereby preparing a pCL_PrhtB-yhhS gene mutant plasmid library.
- the primer sequences used herein are shown in Table 1 below.
- primer vector 13 CACCGGGAGCCCGGGAtgCCCGAACCCGTAGCCGA pCL_PrhtB-yhhS library 14 CTTGCATGCCTGCAGttaAGATGATGAGGCGGCCT 16 CGGGGATCCTCTAGACGCTTGCTGCAACTCTCTCA pCL_PrhtB 17 TACGGGTTCGGGcatGATATCTTTCCTGTGTGAAA
- Recombinant plasmid libraries prepared by the above process were screened using high throughput screening (HTS).
- HTS high throughput screening
- strain CA07-0012 KCCM 11121P, US 8557549 B2 in which the activity of endogenous phosphoserine phosphatase (serB) was weakened in E. coli wild-type strain W3110 was used.
- the prepared pCL_PrhtB-yhhS gene mutant plasmid library was transformed into the base strain CA07-0012 by electroporation, and then an excess of OPS was added medium condition. 3 types of colonies from which growth degradation was canceled were selected by culturing in Then, plasmids were obtained from three selected colonies, and nucleotide sequences were analyzed through sequencing techniques.
- the yhhS gene mutant involved in releasing the growth degradation under the excessive OPS addition condition is selected, and the yhhS gene mutant yhhS M45 having the existing increased OPS excretion activity (U.S. Publication No. 2019-0233859) A1) A better variant was obtained, and it was named yhhS453.
- YhhS453 has the amino acid sequence of SEQ ID NO: 1.
- Example 1 One mutant plasmid pCL_PrhtB-yhhS453 identified in Example 1 was transformed into OPS-producing strain CA07-0012 by electroporation commonly used in the art. Through this, CA07-0012/pCL_PrhtB-yhhS453, an OPS-producing strain into which the yhhS gene mutant yhhS453 was introduced, was prepared, and its O-phosphoserine-producing ability was evaluated.
- each strain was plated on LB solid medium, and then cultured overnight in an incubator at 33°C.
- the strain cultured overnight in LB solid medium was inoculated into the 25mL titer medium shown in Table 2 below, and then incubated for 48 hours in an incubator at 200rpm at 33°C, and the results are shown in Table 3.
- the CA07-0012/pCL_PrhtB-yhhS453 was named Escherichia coli CA07-0352.
- the CA07-0352 strain was deposited with the Korean Culture Center of Microorganisms (KCCM) on May 14, 2020 under the Budapest Treaty and was given an accession number KCCM 12720P.
- serA D-3-phosphoglycerate dehydrogenase, D-3-phosphoglycerate dehydrogenase
- serC 3-phospho Strain CA07-0022/pCL_Prmf-serA*(G336V)-serC (KCCM11103P, US Publication No. US 8557549 B2) with enhanced activity of porcelain aminotransferase, 3-phosphoserine aminotransferase
- yhhS453 was cloned into the HindIII restriction enzyme site of the pCL_Prmf-serA*(G336V)-serC vector.
- yhhS453 gene fragment was obtained through PCR using the primer pair of SEQ ID NOs: 18 and 19. For PCR, denaturation at 94°C for 5 minutes, denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and polymerization at 72°C for 1 minute were repeated 30 times, followed by polymerization at 72°C for 5 minutes.
- the yhhS453 gene fragment obtained through the PCR was cloned using an infusion cloning kit. Cloning was performed by reaction at 50° C. for 60 minutes, and through this, pCL_Prmf-serA*(G336V)-(RBS)serC_PrhtB-yhhS453 mutant plasmid was prepared.
- primer vector 18 CACGGTTAAAAGCTTCGATGGTCGATGATTAAGAC pCL_Prmf-serA*(G336V)-(RBS)serC_PrhtB-yhhS453 19 GATTACGCCAAGCTTttaAGATGATGAGGCGGCCT
- Each of the plasmids prepared above was transformed into an OPS producing strain CA07-0022 by an electroporation method commonly used in the art.
- CA07-0022/pCL_Prmf-serA*(G336V)-(RBS)serC_PrhtB-yhhS453 an OPS-producing strain into which the yhhS gene mutant yhhS453 was introduced, was prepared, and its O-phosphoserine-producing ability was evaluated.
- Each strain was plated on LB solid medium, and then cultured overnight in an incubator at 33°C.
- the strain cultured overnight in LB solid medium was inoculated into the 25ml titer medium of Table 2, and then cultured for 48 hours in an incubator at 200rpm at a temperature of 33°C, and the results are shown in Table 5 below.
- the CA07-0022/pCL_Prmf-serA*(G336V)-(RBS)serC_PrhtB-yhhS453 was named Escherichia coli CA07-0353.
- the CA07-0353 strain was deposited with the Korean Culture Center of Microorganisms (KCCM) on May 14, 2020 under the Budapest Treaty and was given an accession number KCCM 12721P.
- pSKH130 vector SEQ ID NO: 30
- the vector contains R6K replicon, SacB (Levansucrase) gene, and kanamycin resistance gene that are dependent on PI protein (pir gene), and R6K and kanamycin are produced in the first crossover using the vector.
- pSKH130_yhhS453 vector was constructed to replace autologous yhhS in strain CA07-0022 with yhhS453.
- pSKH130-yhhS453 pCL_PrhtB-yhhS453 obtained in Example 1 was used as a template, and PCR was performed using the primer pair of SEQ ID NOs: 20 and 21 to obtain a yhhS453 gene fragment.
- the transformed strain was selected by recombination (crossover), and the strain introduced into the chromosome in LB solid medium with kanamycin was selected, and then excision of the plasmid site from the chromosome was performed through secondary recombination (replacement) in medium with sucrose. .
- the strain CA07-0022::yhhS453 strain was prepared through PCR and sequencing analysis using the primer pair of SEQ ID NOs: 22 and 23 for the strain in which the secondary recombination was completed.
- pSKH130-Ptrc-yhhS453' was prepared. Specifically, using the E. coli wild-type strain W3110 as a template, PCR was performed using the primer pair of SEQ ID NOs: 24 and 25 to obtain a yhhSUP DNA fragment. For PCR, denaturation at 94°C for 5 minutes, denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and polymerization at 72°C for 1 minute were repeated 30 times, followed by polymerization at 72°C for 5 minutes.
- PCR was performed using the primer pair of SEQ ID NOs: 26 and 27 to obtain a DNA fragment of Ptrc.
- denaturation at 94°C for 5 minutes, denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and polymerization at 72°C for 1 minute were repeated 30 times, followed by polymerization at 72°C for 5 minutes.
- PCR was performed using the primer pair of SEQ ID NOs: 28 and 29 using pCL_PrhtB-yhhS453 as a template to obtain a yhhS453 fragment.
- PCR For PCR, denaturation at 94°C for 5 minutes, denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and polymerization at 72°C for 1 minute were repeated 30 times, followed by polymerization at 72°C for 5 minutes.
- pSKH_yhhSUP_Ptrc-yhhS453 was obtained by performing IST with the pSKH130 vector treated with EcoRV. The obtained plasmid was transformed into CA7-0022::yhhS453 strain by electroporation.
- the strain introduced into the chromosome on LB solid medium with kanamycin was selected by primary crossover, and then excision of the plasmid site from the chromosome occurred through secondary recombination (replacement) in medium with sucrose.
- the strain in which the secondary recombination was completed was confirmed using the primer pair of SEQ ID NOs: 22 and 23.
- the prepared strain was named CA07-0022::Ptrc-yhhS453.
- the primer sequences used herein are shown in Table 6 below.
- CA07-0022::Ptrc-yhhS As a control, CA07-0022::Ptrc-yhhS, CA07-0022::Ptrc-yhhS M25, CA07-0022::Ptrc-yhhS M45 strains prepared in the same manner as above were used.
- the nucleotide sequence of the primer used for PCR was the same as above.
- the OPS-producing ability was confirmed.
- each strain was spread on LB solid medium, it was cultured overnight in an incubator at 33° C., and the cultured strains were inoculated into the 25ml titer medium of Table 1 above. Thereafter, the inoculated strain was cultured for 48 hours in an incubator at a temperature of 33° C. at 200 rpm, and the results are shown in Table 7 below.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
서열번호 | 프라이머 | 벡터 |
13 | CACCGGGAGCCCGGGatgCCCGAACCCGTAGCCGA | pCL_PrhtB-yhhS library |
14 | CTTGCATGCCTGCAGttaAGATGATGAGGCGGCCT | |
16 | CGGGGATCCTCTAGACGCTTGCTGCAACTCTCTCA | pCL_PrhtB |
17 | TACGGGTTCGGGcatGATATCTTTCCTGTGTGAAA |
배지성분 | 조제량 |
포도당 | 40g |
KH2PO4(KP1) | 6g |
(NH4)2SO4 | 17g |
MgSO4.7H2O | 1g |
MnSO4.4H2O | 5mg |
FeSO4.7H2O | 10mg |
L-글리신 | 2.5g/L |
호모액기스 | 3g/L |
CaCO3 | 30g/L |
pH | 6.8 |
균주명 | OD562nm | 소모당(g/L) | O-포스포세린(g/L) |
CA07-0012/pCL1920 | 45 | 40 | 1.4 |
CA07-0012/pCL_PrhtB-yhhS | 42.7 | 40 | 1.7 |
CA07-0012/pCL_PrhtB-yhhS M45 | 32 | 40 | 2.3 |
CA07-0012/pCL_PrhtB-yhhS453 | 30 | 40 | 3.1 |
서열번호 | 프라이머 | 벡터 |
18 | CACGGTTAAAAGCTTCGATGGTCGATGATTAAGAC | pCL_Prmf-serA*(G336V)-(RBS)serC_PrhtB-yhhS453 |
19 | GATTACGCCAAGCTTttaAGATGATGAGGCGGCCT |
균주명 | OD562nm | 소모당(g/L) | O-포스포세린(g/L) |
CA07-0022/pCL_Prmf-serA*(G336V)-(RBS)serC_PrhtB-yhhS(wt) | 30 | 40 | 4.01 |
CA07-0022/pCL_Prmf-serA*(G336V)-(RBS)serC_PrhtB-yhhS M25 | 26.3 | 40 | 6.01 |
CA07-0022/pCL_Prmf-serA*(G336V)-(RBS)serC_PrhtB-yhhS M45 | 25.4 | 40 | 4.8 |
CA07-0022/pCL_Prmf-serA*(G336V)-(RBS)serC_PrhtB-yhhS453 | 25.1 | 40 | 7.5 |
서열번호 | 프라이머 | 벡터 |
20 | CAGGAATTCGATATCATGCCCGAACCCGTAGCCGA | pSK-yhhS453 |
21 | GACTAGCGTGATATCTTAAGATGATGAGGCGGCCT | |
22 | ATGTGAATCTGTGGATTATT | yhhS-out |
23 | GTTATGGCCGTTTATCGAAA | |
24 | CAGGAATTCGATATCTCGCTCCGGCGACATATGCA | pSKH130-Ptrc-yhhS453' |
25 | CAGCAAGCGGGTACCGAGGATCACCACATTTTTAC | |
26 | AATGTGGTGATCCTCGGTACCCGCTTGCTGCAACT | |
27 | TACGGGTTCGGGCATGATATCTTTCCTGTGTGAAA | |
28 | CACAGGAAAGATATCATGCCCGAACCCGTAGCCGA | |
29 | GACTAGCGTGATATCGCACCCATCGCCATCGCCCC |
균주명 | OD562nm | 소모당(g/L) | O-포스포세린(g/L) |
CA07-0022/pCL_Prmf-serA*(G336V)-(RBS)serC | 32 | 40 | 1.7 |
CA07-0022::Ptrc-yhhS/pCL_Prmf-serA*(G336V)-(RBS)serC | 33 | 40 | 2.0 |
CA07-0022::Ptrc-yhhS M25/pCL_Prmf-serA*(G336V)-(RBS)serC | 35 | 40 | 3.2 |
CA07-0022::Ptrc-yhhS M45/pCL_Prmf-serA*(G336V)-(RBS)serC | 25.4 | 40 | 2.7 |
CA07-0022::Ptrc-yhhS453/pCL_Prmf-serA*(G336V)-(RBS)serC | 25.1 | 40 | 5.0 |
Claims (14)
- 서열번호 11의 아미노산 서열의 a) 241번째에 상응하는 위치의 이소류신(I)이 트레오닌(T)으로, 246번째에 상응하는 위치의 아스파르트산(D)이 발린(V)으로, 330번째에 상응하는 위치의 발린(V)이 이소류신(I)으로의 치환을 포함하고, b) 88번째에 상응하는 위치의 아미노산이 페닐알라닌이고, c) 207번째에 상응하는 위치의 아미노산이 라이신(K)인 서열을 가지는, O-포스포세린(O-phosphoserine, OPS) 배출 활성을 나타내는 폴리펩타이드.
- 제1항에 있어서, 상기 폴리펩타이드는 서열번호 1의 아미노산 서열 및 이와 90% 이상의 서열 동일성을 가지는, O-포스포세린(O-phosphoserine, OPS) 배출 활성을 나타내는 폴리펩타이드.
- 제1항의 폴리펩타이드를 코딩하는 폴리뉴클레오타이드.
- 제1항의 폴리펩타이드, 상기 폴리펩타이드를 코딩하는 폴리뉴클레오타이드 및 상기 폴리뉴클레오타이드를 포함하는 벡터 중 어느 하나 이상을 포함하는, O-포스포세린 생산 미생물.
- 제4항에 있어서, 상기 미생물은 추가로 포스포세린 포스파타아제(phosphoserine phosphatase, SerB)의 활성이 내재적 활성에 비해 약화된, 미생물.
- 제4항에 있어서, 상기 미생물은 추가로 포스포글리세라이트 디하이드로게나제(phosphoglycerate dehydrogenase, SerA) 또는 포스포세린 아미노트랜스퍼라제(phosphoserine aminotransferase, SerC)의 활성이 내재적 활성에 비해 강화된, 미생물.
- 제4항에 있어서, 상기 미생물은 에스케리키아 콜라이(Escherichia coli)인, 미생물.
- 제1항의 폴리펩타이드, 상기 폴리펩타이드를 코딩하는 폴리뉴클레오타이드 및 상기 폴리뉴클레오타이드를 포함하는 벡터 중 어느 하나 이상을 포함하는, O-포스포세린 생산 미생물을 배지에서 배양하는 단계를 포함하는, O-포스포세린의 생산 방법.
- 제8항에 있어서, 상기 방법은 배양된 배지 또는 미생물에서 O-포스포세린을 회수하는 단계를 추가로 포함하는, O-포스포세린의 생산 방법.
- a) 제1항의 폴리펩타이드, 상기 폴리펩타이드를 코딩하는 폴리뉴클레오타이드 및 상기 폴리뉴클레오타이드를 포함하는 벡터 중 어느 하나 이상을 포함하는, O-포스포세린 생산 미생물을 배지에서 배양하여 O-포스포세린 또는 이를 포함하는 배지를 생산하는 단계; 및b) O-포스포세린 설프하이드릴라아제(O-phosphoserine sulfliydrylase, OPSS) 또는 이를 발현하는 미생물의 존재 하에, 상기 a) 단계에서 생산된 O-포스포세린 또는 이를 포함하는 배지를 황화물과 반응시키는 단계를 포함하는, 시스테인 또는 이의 유도체의 생산 방법.
- 제10항에 있어서, 상기 시스테인 유도체의 생산 방법은 상기 b) 단계에서 생성된 시스테인을 시스테인 유도체로 전환시키는 단계를 추가로 포함하는, 시스테인 또는 이의 유도체의 생산 방법.
- 제10항에 있어서, 상기 황화물은 Na2S, NaSH, (NH4)2S, H2S 및 Na2S2O3로 이루어지는 군으로부터 선택되는 하나 이상인, 시스테인 또는 이의 유도체의 생산 방법.
- 서열번호 11의 아미노산 서열의 a) 241번째에 상응하는 위치의 이소류신(I)이 트레오닌(T)으로, 246번째에 상응하는 위치의 아스파르트산(D)이 발린(V)으로, 330번째에 상응하는 위치의 발린(V)이 이소류신(I)으로의 치환을 포함하고, b) 88번째에 상응하는 위치의 아미노산이 페닐알라닌이고, c) 207번째에 상응하는 위치의 아미노산이 라이신(K)인 서열을 가지는 O-포스포세린 배출 활성을 나타내는 폴리펩타이드 또는 서열번호 1의 아미노산 서열을 가지는 폴리펩타이드의 O-포스포세린, 시스테인 또는 시스테인의 유도체 생산 용도.
- 서열번호 11의 아미노산 서열의 a) 241번째에 상응하는 위치의 이소류신(I)이 트레오닌(T)으로, 246번째에 상응하는 위치의 아스파르트산(D)이 발린(V)으로, 330번째에 상응하는 위치의 발린(V)이 이소류신(I)으로의 치환을 포함하고, b) 88번째에 상응하는 위치의 아미노산이 페닐알라닌이고, c) 207번째에 상응하는 위치의 아미노산이 라이신(K)인 서열을 가지는 O-포스포세린 배출 활성을 나타내는 폴리펩타이드 또는 서열번호 1의 아미노산 서열을 가지는 폴리펩타이드의 O-포스포세린을 미생물로부터 배출하는 용도.
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020227010528A KR20220062542A (ko) | 2020-06-09 | 2021-06-08 | O-포스포세린 배출 단백질 변이체 및 이를 이용한 o-포스포세린, 시스테인 및 이의 유도체의 생산방법 |
BR112022013303A BR112022013303A2 (pt) | 2020-06-09 | 2021-06-08 | Polipeptídeo com atividade de exportação de o-fosfoserina (ops), micro-organismo produtor de o-fosfoserina, métodos e usos |
CN202180007420.0A CN115605496A (zh) | 2020-06-09 | 2021-06-08 | O-磷酸丝氨酸输出蛋白变体和利用其生产o-磷酸丝氨酸、半胱氨酸及其衍生物的方法 |
JP2022536603A JP7407941B2 (ja) | 2020-06-09 | 2021-06-08 | O-ホスホセリン排出タンパク質変異体、並びにそれを用いたo-ホスホセリン、システイン及びその誘導体の生産方法 |
CA3163410A CA3163410A1 (en) | 2020-06-09 | 2021-06-08 | O-phosphoserine export protein variant and method for producing o-phosphoserine, cysteine, and derivatives thereof using the same |
AU2021288230A AU2021288230B2 (en) | 2020-06-09 | 2021-06-08 | O-phosphoserine export protein variant and method for producing O-phosphoserine, cysteine, and derivative thereof by using same |
EP21822283.4A EP4053147A4 (en) | 2020-06-09 | 2021-06-08 | O-PHOSPHOSERIN EXPORT PROTEIN VARIANT AND PROCESS FOR THE PREPARATION OF O-PHOSPHOSERIN, CYSTEINE AND A DERIVATIVE THEREOF USING SAME |
US17/756,527 US20230127940A1 (en) | 2020-06-09 | 2021-06-08 | O-phosphoserine export protein variant and method for producing o-phosphoserine, cysteine, and derivatives thereof using the same |
MX2022008308A MX2022008308A (es) | 2020-06-09 | 2021-06-08 | Variante de proteina de exportacion de o-fosfoserina y procedimiento de produccion de o-fosfoserina, cisteina y derivados de las mismas mediante su uso. |
ZA2022/06111A ZA202206111B (en) | 2020-06-09 | 2022-06-01 | O-phosphoserine export protein variant and method for producing o-phosphoserine, cysteine, and derivatives thereof using the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0069753 | 2020-06-09 | ||
KR20200069753 | 2020-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021251734A1 true WO2021251734A1 (ko) | 2021-12-16 |
Family
ID=78846380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/007172 WO2021251734A1 (ko) | 2020-06-09 | 2021-06-08 | O-포스포세린 배출 단백질 변이체 및 이를 이용한 o-포스포세린, 시스테인 및 이의 유도체의 생산방법 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230127940A1 (ko) |
EP (1) | EP4053147A4 (ko) |
JP (1) | JP7407941B2 (ko) |
KR (1) | KR20220062542A (ko) |
CN (1) | CN115605496A (ko) |
AR (1) | AR122565A1 (ko) |
AU (1) | AU2021288230B2 (ko) |
BR (1) | BR112022013303A2 (ko) |
CA (1) | CA3163410A1 (ko) |
MX (1) | MX2022008308A (ko) |
WO (1) | WO2021251734A1 (ko) |
ZA (1) | ZA202206111B (ko) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972663A (en) | 1997-06-19 | 1999-10-26 | Consortium Fur Elektrochemische Industrie Gmbh | Microorganisms and processes for the fermentative preparation of L-cysteine, L-cystine, N-acetylserine or thiazolidine derivatives |
US6258573B1 (en) | 1998-01-12 | 2001-07-10 | Ajinomoto Co., Inc. | Method of producing L-serine by fermentation |
US7662943B2 (en) | 2004-12-16 | 2010-02-16 | Cj Cheiljedang Corporation | Promoter sequences from Corynebacterium ammoniagenes |
US8557549B2 (en) | 2010-10-20 | 2013-10-15 | CJ Cheildjedang Corporation | Microorganism producing O-phosphoserine and method of producing L-cysteine or derivatives thereof from O-phosphoserine using the same |
KR20140133754A (ko) * | 2013-05-10 | 2014-11-20 | 씨제이제일제당 (주) | 신규 o-포스포세린 배출 단백질 및 이를 이용한 o-포스포세린의 생산방법 |
US9127324B2 (en) | 2010-10-20 | 2015-09-08 | CJ Cheildjedang Corporation | O-phosphoserine sulfhydrylase mutants and method for production of cysteine using the same |
KR20160020050A (ko) * | 2014-08-12 | 2016-02-23 | 씨제이제일제당 (주) | O-포스포세린 생산 미생물 및 이를 이용한 o-포스포세린 또는 l-시스테인 생산 방법 |
KR101694632B1 (ko) * | 2015-09-11 | 2017-01-10 | 씨제이제일제당 (주) | 신규 o-포스포세린 배출 단백질 변이체 및 이를 이용한 o-포스포세린, 시스테인 및 이의 유도체의 생산방법 |
US20170247727A1 (en) | 2014-06-03 | 2017-08-31 | Cj Cheiljedang Corporation | Microorganism having ability to produce o-succinylhomoserine or succinic acid, and method for producing succinic acid or o-succinylhomoserine by using same |
-
2021
- 2021-06-08 BR BR112022013303A patent/BR112022013303A2/pt unknown
- 2021-06-08 CA CA3163410A patent/CA3163410A1/en active Pending
- 2021-06-08 EP EP21822283.4A patent/EP4053147A4/en active Pending
- 2021-06-08 CN CN202180007420.0A patent/CN115605496A/zh active Pending
- 2021-06-08 AU AU2021288230A patent/AU2021288230B2/en active Active
- 2021-06-08 JP JP2022536603A patent/JP7407941B2/ja active Active
- 2021-06-08 AR ARP210101556A patent/AR122565A1/es unknown
- 2021-06-08 US US17/756,527 patent/US20230127940A1/en active Pending
- 2021-06-08 KR KR1020227010528A patent/KR20220062542A/ko not_active Application Discontinuation
- 2021-06-08 WO PCT/KR2021/007172 patent/WO2021251734A1/ko active Application Filing
- 2021-06-08 MX MX2022008308A patent/MX2022008308A/es unknown
-
2022
- 2022-06-01 ZA ZA2022/06111A patent/ZA202206111B/en unknown
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972663A (en) | 1997-06-19 | 1999-10-26 | Consortium Fur Elektrochemische Industrie Gmbh | Microorganisms and processes for the fermentative preparation of L-cysteine, L-cystine, N-acetylserine or thiazolidine derivatives |
US6258573B1 (en) | 1998-01-12 | 2001-07-10 | Ajinomoto Co., Inc. | Method of producing L-serine by fermentation |
US20030008358A1 (en) * | 1998-01-12 | 2003-01-09 | Ajinomoto Co. Inc | Method of producing L-serine by fermentation |
US7662943B2 (en) | 2004-12-16 | 2010-02-16 | Cj Cheiljedang Corporation | Promoter sequences from Corynebacterium ammoniagenes |
US8557549B2 (en) | 2010-10-20 | 2013-10-15 | CJ Cheildjedang Corporation | Microorganism producing O-phosphoserine and method of producing L-cysteine or derivatives thereof from O-phosphoserine using the same |
US9127324B2 (en) | 2010-10-20 | 2015-09-08 | CJ Cheildjedang Corporation | O-phosphoserine sulfhydrylase mutants and method for production of cysteine using the same |
KR20140133754A (ko) * | 2013-05-10 | 2014-11-20 | 씨제이제일제당 (주) | 신규 o-포스포세린 배출 단백질 및 이를 이용한 o-포스포세린의 생산방법 |
US20170247727A1 (en) | 2014-06-03 | 2017-08-31 | Cj Cheiljedang Corporation | Microorganism having ability to produce o-succinylhomoserine or succinic acid, and method for producing succinic acid or o-succinylhomoserine by using same |
KR20160020050A (ko) * | 2014-08-12 | 2016-02-23 | 씨제이제일제당 (주) | O-포스포세린 생산 미생물 및 이를 이용한 o-포스포세린 또는 l-시스테인 생산 방법 |
KR101694632B1 (ko) * | 2015-09-11 | 2017-01-10 | 씨제이제일제당 (주) | 신규 o-포스포세린 배출 단백질 변이체 및 이를 이용한 o-포스포세린, 시스테인 및 이의 유도체의 생산방법 |
US20190233859A1 (en) | 2015-09-11 | 2019-08-01 | Cj Cheiljedang Corporation | Novel o-phosphoserine efflux protein variant and method for producing o-phosphoserine, cysteine and derivative thereof using same |
Non-Patent Citations (22)
Title |
---|
"Atlas of Protein Sequence and Structure", 1979, NATIONAL BIOMEDICAL RESEARCH FOUNDATION, pages: 353 - 358 |
"Guide to Huge Computers", 1994, ACADEMIC PRESS |
"Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
AHMED ZAHOOR, COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, vol. 3, October 2012 (2012-10-01) |
ATSCHUL, S. F. ET AL., J MOLEC BIOL, vol. 215, 1990, pages 403 |
BURNS K. E. ET AL., J. AM. CHEM. SOC., vol. 127, 2005, pages 11602 - 11603 |
CARILLO ET AL., SIAM J APPLIED MATH, vol. 48, 1988, pages 1073 |
DATABASE PROTEIN 16 December 2020 (2020-12-16), ANONYMOUS : "MULTISPECIES: MFS transporter [Enterobacteriaceae] ", XP055879342, retrieved from NCBI Database accession no. WP_001300943 * |
DEVEREUX, J. ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, 1984, pages 387 |
GRANT G. A. ET AL., BIOCHEM., vol. 39, 2000, pages 7316 - 7319 |
GRANT G. A. ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 17844 - 17850 |
GRANT G. A. ET AL., J. BIOL. CHEM., vol. 39, 1999, pages 5357 - 5361 |
GRIBSKOV ET AL., NUCL. ACIDS RES., vol. 14, 1986, pages 6745 |
MINO K.ISHIKAWA K., FEBS LETTERS, vol. 551, 2003, pages 133 - 138 |
NEEDLEMAN ET AL., J MOL BIOL., vol. 48, 1970, pages 443 |
NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 - 453 |
PEARSON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 2444 |
PETERS-WENDISCH P. ET AL., APPL. MICROBIOL. BIOTECHNOL., vol. 60, 2002, pages 37 - 441 |
PETERS-WENDISCH P., APPL ENVIRON MICROBIOL, vol. 71, no. 11, November 2005 (2005-11-01), pages 7139 - 44 |
RICE ET AL.: "EMBOSS: The European Molecular Biology Open Software Suite", TRENDS GENET, vol. 16, 2000, pages 276 - 277, XP004200114, DOI: 10.1016/S0168-9525(00)02024-2 |
WADA MTAKAGI H, APPL. MICROBIOL. BIOCHEM., vol. 73, 2006, pages 48 - 54 |
WENDISCH V. F. ET AL., CURR OPIN MICROBIOL, vol. 9, no. 3, June 2006 (2006-06-01), pages 268 - 74 |
Also Published As
Publication number | Publication date |
---|---|
EP4053147A4 (en) | 2023-01-25 |
AR122565A1 (es) | 2022-09-21 |
EP4053147A1 (en) | 2022-09-07 |
CN115605496A (zh) | 2023-01-13 |
AU2021288230B2 (en) | 2023-08-17 |
ZA202206111B (en) | 2023-09-27 |
US20230127940A1 (en) | 2023-04-27 |
JP2023506054A (ja) | 2023-02-14 |
AU2021288230A1 (en) | 2022-06-09 |
CA3163410A1 (en) | 2021-12-16 |
JP7407941B2 (ja) | 2024-01-04 |
MX2022008308A (es) | 2022-08-08 |
BR112022013303A2 (pt) | 2022-12-20 |
KR20220062542A (ko) | 2022-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019004778A2 (ko) | 신규한 아스파토키나제 변이체 및 이를 이용한 l-아미노산의 제조방법 | |
WO2022163934A1 (ko) | 신규한 d-알라닌-d-알라닌 리가아제 a 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022055094A1 (ko) | L-글루탐산 생산 재조합 미생물 및 이를 이용한 l-글루탐산의 제조방법 | |
WO2022163933A1 (ko) | 신규한 abc 트랜스포터 atp-결합 단백질 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022163917A1 (ko) | 신규한 단백질 변이체 및 이를 이용한 l-발린 생산 방법 | |
WO2022163920A1 (ko) | 신규한 시스테인 설피네이트 디설피나제 변이체 및 이를 이용한 l-발린 생산 방법 | |
WO2022163935A1 (ko) | 신규한 글루코사민-6-포스페이트 디아미나제 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022154191A1 (ko) | 신규한 2,5-다이케토-d-글루콘산 리덕타제 변이체 및 이를 이용한 xmp 또는 gmp 생산 방법 | |
WO2022154190A1 (ko) | 신규한 포스포노아세테이트 하이드롤라제 변이체 및 이를 이용한 xmp 또는 gmp 생산 방법 | |
WO2022163922A1 (ko) | 신규한 아스파라긴 신타제 변이체 및 이를 이용한 l-발린 생산 방법 | |
WO2022154181A1 (ko) | 신규한 1,4-알파-글루칸-분지 효소 변이체 및 이를 이용한 imp 생산 방법 | |
WO2022163923A1 (ko) | 신규한 atp 포스포리보실트랜스퍼라제 변이체 및 이를 이용한 l-발린 생산 방법 | |
WO2021251734A1 (ko) | O-포스포세린 배출 단백질 변이체 및 이를 이용한 o-포스포세린, 시스테인 및 이의 유도체의 생산방법 | |
WO2022260215A1 (ko) | 신규한 mdth 변이체 및 이를 이용한 o-포스포세린, 시스테인 및 이의 유도체의 생산방법 | |
WO2022163937A1 (ko) | 신규한 abc 트랜스포터 atp-결합 단백질 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022055192A1 (ko) | 신규 o-포스포세린 배출 단백질 및 이를 이용한 o-포스포세린, 시스테인 및 이의 유도체의 생산 방법 | |
WO2022163936A1 (ko) | 신규한 엑시뉴클레아제 abc 서브유닛 a 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022163938A1 (ko) | 신규한 리보뉴클레아제 p 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022154189A1 (ko) | 신규한 피토엔 신타제 변이체 및 이를 이용한 xmp 또는 gmp 생산 방법 | |
WO2022163929A1 (ko) | 신규한 펩티딜-디펩티다제 변이체 및 이를 이용한 xmp 또는 gmp 생산 방법 | |
WO2022163939A1 (ko) | 신규한 mfs 트랜스포터 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2022154173A1 (ko) | 신규한 abc 트랜스포터 atp-결합 단백질 변이체 및 이를 이용한 l-라이신 생산 방법 | |
WO2022163919A1 (ko) | 신규한 우레아제 부속 단백질 변이체 및 이를 이용한 l-발린 생산 방법 | |
WO2022154188A1 (ko) | 신규한 폴리케타이드 신타제 변이체 및 이를 이용한 xmp 또는 gmp 생산 방법 | |
WO2022163926A1 (ko) | 신규한 프롤린 탈수소효소 변이체 및 이를 이용한 l-발린 생산 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21822283 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20227010528 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021822283 Country of ref document: EP Effective date: 20220531 |
|
ENP | Entry into the national phase |
Ref document number: 2021288230 Country of ref document: AU Date of ref document: 20210608 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2022536603 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3163410 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022013303 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202217045902 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 112022013303 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220701 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022114846 Country of ref document: RU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |